|
Apolipoprotein C-III Deficiency
|
0.610 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Apolipoprotein C-III Deficiency
|
0.610 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Apolipoprotein C-III Deficiency
|
0.610 |
GeneticVariation
|
disease |
BEFREE |
D25V apolipoprotein C-III is a new human amyloidogenic protein and the first conferring cardioprotection even in the unfavourable context of renal failure, extending the evidence for an important cardiovascular protective role of apolipoprotein C-III deficiency.
|
26790392 |
2016 |
|
Apolipoprotein C-III Deficiency
|
0.610 |
GeneticVariation
|
disease |
UNIPROT |
Apolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia.
|
2022742 |
1991 |
|
Hypercholesterolemia
|
0.460 |
GeneticVariation
|
disease |
BEFREE |
Hypercholesterolemia is associated with the apolipoprotein C-III (APOC3) genotype in children receiving HAART: an eight-year retrospective study.
|
22848358 |
2012 |
|
Hypercholesterolemia
|
0.460 |
GeneticVariation
|
disease |
BEFREE |
Multivariate logistic regression analysis with adjustment for age, body mass index, and the prevalence of smoking, hypertension, diabetes mellitus, and hyperuricemia revealed that three polymorphisms [994G --> T (Val279Phe) in the platelet-activating factor acetylhydrolase gene, 242C --> T (His72Tyr) in the NADH/NADPH oxidase p22 phox gene, and 1100C --> T in the apolipoprotein C-III gene] were significantly associated with CAD in men with hypercholesterolemia.
|
14709372 |
2004 |
|
Hypercholesterolemia
|
0.460 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
|
Hypercholesterolemia
|
0.460 |
Biomarker
|
disease |
BEFREE |
Vitamin D supplementation significantly increased total cholesterol, triglycerides, very-low-density lipoprotein (VLDL) triglycerides, low-density lipoprotein (LDL) triglycerides, high-density lipoprotein (HDL) triglycerides, apolipoprotein B (ApoB), LDL-ApoB, ApoCII, ApoCIII, phospholipids, and ApoE (P < .05 for all).
|
29653812 |
2019 |
|
Hypercholesterolemia
|
0.460 |
Biomarker
|
disease |
BEFREE |
This study shows the relevance of polymorphisms in APOB (odds ratio (OR), 1.17; 95% confidence interval (95% CI), 0.74-1.85), APOC3 (OR, 1.33; 95% CI, 0.82-2.17) and APOE (OR, 1.75; 95% CI, 1.09-2.80), as genetic risk markers for hypercholesterolemia; polymorphisms in ACE (OR, 1.68; 95% CI, 0.32-8.77) and AGT (OR, 1.74; 95% CI, 0.97-3.14) for hypertension; and in APOE*3/*4 (OR, 2.06; 95% CI, 1.70-2.51) and APOE*4/*4 (OR, 3.08; 95% CI, 1.85-5.12) as unambiguous markers of dementia.
|
29081697 |
2017 |
|
Hypercholesterolemia
|
0.460 |
Biomarker
|
disease |
BEFREE |
About 80 genes are associated with hypercholesterolemia but only pharmaceuticals that inhibit cholesteryl ester transfer protein (CETP), angiopoietin-related protein 3 (ANGPTL3), and apolipoprotein C-III (apoC-III) have recently been tested in clinical trials.
|
29356705 |
2018 |
|
Hypercholesterolemia
|
0.460 |
Biomarker
|
disease |
BEFREE |
Hypercholesterolemics, in contrast, were distinguished from the normolipidemic group by 2-fold higher concentrations of apoB lipoproteins without apoE or apoC-III (E(-)C-III(-)), mainly LDL, which had high cholesterol content.
|
11483625 |
2001 |
|
Hypercholesterolemia
|
0.460 |
Biomarker
|
disease |
HPO |
|
|
|
|
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein C-III (apoC-III), a small proinflammatory protein present on 6% to 7% of high-density lipoprotein (HDL) particles, defines a subspecies of HDL adversely associated with coronary heart disease in primarily white cohorts.
|
29540426 |
2018 |
|
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study.
|
30249512 |
2019 |
|
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Within the apolipoprotein A-I-C-III-A-IV gene cluster, the Ssti polymorphism in the 3' untranslated region of the apolipoprotein C-III gene is the variant site most consistently and strongly associated with raised plasma triglyceride levels and coronary artery disease.
|
9211063 |
1997 |
|
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The multivariate model included 512 men with coronary artery disease from the REGRESS study who were completely genotyped for eight polymorphisms selected in the univariate procedure (ie, APOA1 G(-75)A, ABCA1 C(-477)T, ABCA1 G1051A, APOC3 T3206G, APOE Arg158Cys, LIPC C(-514)T, LPL Asn291Ser and LPL Ser447Stop).
|
15657615 |
2005 |
|
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Lack of association between apolipoprotein C3 gene polymorphisms and risk of coronary heart disease in a Han population in East China.
|
22054125 |
2011 |
|
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
APOC3 polymorphisms were associated with lipid parameters and coronary artery disease in several populations but not all.
|
17367769 |
2007 |
|
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
ApoC-III gene polymorphisms and risk of coronary artery disease.
|
12235176 |
2002 |
|
Coronary Arteriosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
It is effective in decreasing triglycerides by targeting apoC3 levels in patients with coronary heart disease.
|
30511426 |
2019 |
|
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Heterozygous deficiency of APOC3 has been shown to protect against coronary heart disease; we identified APOC3 homozygous pLoF carriers in our cohort.
|
28406212 |
2017 |
|
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Sialylated isoforms of apolipoprotein C-III and plasma lipids in subjects with coronary artery disease.
|
29652662 |
2018 |
|
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
An APOC3 3'UTR variant associated with plasma triglycerides levels and coronary heart disease by creating a functional miR-4271 binding site.
|
27624799 |
2016 |
|
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Emerging evidences for the opposite role of apolipoprotein C3 and apolipoprotein A5 in lipid metabolism and coronary artery disease.
|
31836003 |
2019 |
|
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Synergistic effects of the apolipoprotein E epsilon3/epsilon2/epsilon4, the cholesteryl ester transfer protein TaqIB, and the apolipoprotein C3 -482 C>T polymorphisms on their association with coronary artery disease.
|
18289550 |
2008 |